For the fiscal year ended September 2026, net loss widened. Revenue increased due to API supply to Claris and a one-time contract payment from Maruishi Pharmaceutical, but operating loss expanded substantially due to increased R&D expenses and the upfront recording of commercial formulation development costs for vocal fold scarring. For fiscal 2027, revenue is expected to increase, but R&D spending is expected to remain elevated.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Kringle Pharma, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4884-20261113-01.pdf","jir_short_summary":"For the fiscal year ended September 2026, net loss widened. Revenue increased due to API supply to Claris and a one-time contract payment from Maruishi Pharmaceutical, but operating loss expanded substantially due to increased R&D expenses and the upfront recording of commercial formulation development costs for vocal fold scarring. For fiscal 2027, revenue is expected to increase, but R&D spending is expected to remain elevated.","jir_summary":"### Overview of Results\nFor the fiscal year ended September 2026, revenue increased due to API supply to Claris and receipt of a one-time contract payment, while higher R&D expenses and the recording of costs for the commercial formulation development for vocal fold scarring weighed heavily, leading to a significant expansion of operating loss. Ordinary loss has trended lower but remains in deficit. Strengthening manufacturing capabilities for U.S. and overseas expansion and preparations for an additional Phase III trial are ongoing.\n\n### Outlook and Funding\nFor the fiscal year ending September 2027, revenue is expected to increase, but the impact of higher R&D spending and organizational strengthening costs will continue. Funding will utilize the \"TIP\" program to prepare for the U.S. Phase III trial and accelerate overseas expansion. The allocation of funds is clarified to realize the three-pronged strategy (two domestic product launches, overseas expansion, and indication expansion).","jir_financial_highlights":"Revenue: 442 million yen (Year-over-year: Unknown \/ Drivers: API supply to Claris and one-time contract payment)\nOperating Loss: -813 million yen (Narrowed from -1,172 million yen in the prior year)\nNet Loss Attributable to Owners of Parent: -813 million yen (Improved from -1,173 million yen in the prior year)\nCash and Cash Equivalents at Period-End: 1,053 million yen (Increased from 991 million yen at the end of the prior period)","jir_category":"","jir_hashtags":"#KringlePharma, #Earnings, #CapitalPolicy","jir_key_figures":"Revenue: 442 million yen\nNet Loss Attributable to Owners of Parent: -813 million yen\nCash and Cash Equivalents at Period-End: 1,053 million yen","jir_meta_title":"Kringle Pharma, Inc. FY2026 Earnings | Revenue Up from Claris API Supply but Final Results in Loss","jir_meta_description":"Key points from Kringle Pharma, Inc.'s fiscal 2026 earnings presentation: drivers of revenue growth, reasons for widened deficit due to increased development expenses, and outlook and funding strategy.","jir_og_title":"Kringle Pharma, Inc. Earnings Summary: Revenue Up but Loss Widens \u2014 Strategy and Funding Ahead","jir_og_description":"Summary of FY2026 results: revenue drivers and reasons for widened deficit, FY2027 outlook, and funding plans.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/9\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[72,442]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income (Loss) Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/9\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (Loss)\\\",\\\"data\\\":[-909,-813]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/9\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[-916,-813]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"cash_balance\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Cash and Cash Equivalents\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/9\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Cash Balance\\\",\\\"data\\\":[991,1053]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"funds_allocation\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Breakdown of Use of Funds\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Preparation for U.S. Phase III Trial\\\",\\\"New API Manufacturing Method\\\",\\\"Domestic API Manufacturing\\\",\\\"Working Capital\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Amount (million yen)\\\",\\\"data\\\":[678,640,310,577]}]},\\\"options\\\":{}}\"}]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-153073","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n